121 related articles for article (PubMed ID: 10194138)
21. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
[TBL] [Abstract][Full Text] [Related]
22. A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia.
Dutcher JP; Morris EL; Gaynor B; Paietta E; Wiernik PH
Med Oncol; 2010 Sep; 27(3):728-35. PubMed ID: 19697165
[TBL] [Abstract][Full Text] [Related]
23. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia.
Carella AM; Chimirri F; Podestà M; Pitto A; Piaggio G; Dejana A; Lerma E; Pollicardo N; Vassallo F; Soracco M; Benvenuto F; Valbonesi M; Carlier P; Vimercati R; Prencipe E; Gatti AM; Ferrara RA; Incagliato M; Florio G; Frassoni F
Bone Marrow Transplant; 1996 Feb; 17(2):201-5. PubMed ID: 8640167
[TBL] [Abstract][Full Text] [Related]
24. Interferon-alpha combined with cytarabine in chronic myelogenous leukemia - clinical benefits.
Lindauer M; Fischer T
Leuk Lymphoma; 2001 May; 41(5-6):523-33. PubMed ID: 11378570
[TBL] [Abstract][Full Text] [Related]
25. Prolonged hematological remission by mitoxantrone and interferon--alpha-2b in a child with resistant Philadelphia chromosome-positive chronic myelogenous leukemia.
Duru F; Tuncer M; Hiçsönmez G
Eur J Haematol; 1993 Sep; 51(3):173-4. PubMed ID: 8405332
[No Abstract] [Full Text] [Related]
26. Idarubicin and intermediate-dose cytarabine for myeloid blast crisis of chronic myelogenous leukemia--results of a phase-II trial.
Schneller F; Schuler M; Schumacher K; Thaler J; Peschel C; Huber C; Aulitzky W
Ann Hematol; 1998 Nov; 77(5):225-9. PubMed ID: 9858148
[TBL] [Abstract][Full Text] [Related]
27. Treatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methylprednisolone.
Bolaman Z; Köseoğlu M; Ayyildiz O; Kadiköylü G; Sönmez HM; Demir S; Müftüoğlu E
Haematologia (Budap); 2002; 32(1):49-57. PubMed ID: 12243555
[TBL] [Abstract][Full Text] [Related]
28. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.
Sacchi S; Kantarjian HM; O'Brien S; Cortes J; Rios MB; Giles FJ; Beran M; Koller CA; Keating MJ; Talpaz M
Cancer; 1999 Dec; 86(12):2632-41. PubMed ID: 10594858
[TBL] [Abstract][Full Text] [Related]
29. Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase.
Maloisel F; Guerci A; Guyotat D; Ifrah N; Michallet M; Reiffers J; Tertain G; Blanc M; Bauduer F; Brière J; Abgrall JF; Pegourie-Bandelier B; Solary E; Cambier N; Coso D; Vilque JP; Delain M; Harousseau JL; Rousselot P; Belhadj K; Morice P; Attal J; Chabin M; Chastang C; Guilhot J; Guilhot F;
Leukemia; 2002 Apr; 16(4):573-80. PubMed ID: 11960335
[TBL] [Abstract][Full Text] [Related]
30. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.
Hehlmann R; Berger U; Pfirrmann M; Hochhaus A; Metzgeroth G; Maywald O; Hasford J; Reiter A; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Griesshammer M; Nerl C; Kuse R; Tobler A; Eimermacher H; Tichelli A; Aul C; Wilhelm M; Fischer JT; Perker M; Scheid C; Schenk M; Weiss J; Meier CR; Kremers S; Labedzki L; Schmeiser T; Lohrmann HP; Heimpel H;
Leukemia; 2003 Aug; 17(8):1529-37. PubMed ID: 12886239
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: a study of the Eastern Cooperative Oncology Group.
Dutcher JP; Eudey L; Wiernik PH; Paietta E; Bennett JM; Arlin Z; Kellermeyer R; Rowe J; O'Connell M; Oken M
Leukemia; 1992 Aug; 6(8):770-5. PubMed ID: 1379312
[TBL] [Abstract][Full Text] [Related]
32. A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia.
Amadori S; Picardi A; Fazi P; Testi AM; Petti MC; Montefusco E; Mandelli F
Leukemia; 1996 May; 10(5):766-8. PubMed ID: 8656669
[TBL] [Abstract][Full Text] [Related]
33. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group.
Guilhot F; Chastang C; Michallet M; Guerci A; Harousseau JL; Maloisel F; Bouabdallah R; Guyotat D; Cheron N; Nicolini F; Abgrall JF; Tanzer J
N Engl J Med; 1997 Jul; 337(4):223-9. PubMed ID: 9227927
[TBL] [Abstract][Full Text] [Related]
34. Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia.
Sacchi S; Kantarjian HM; Freireich EJ; O'Brien S; Cortes J; Rios MB; Kornblau S; Giles FJ; Koller C; Gajewski J; Talpaz M
Leuk Lymphoma; 1999 Nov; 35(5-6):483-9. PubMed ID: 10609785
[TBL] [Abstract][Full Text] [Related]
35. Initial cytoreduction by mitoxantrone and cytarabine has no impact on the outcome of interferon-alfa-2b therapy in chronic myelogenous leukemia.
Nielsen H; Nielsen JL; Karle H
Eur J Haematol; 1992 Aug; 49(2):67-70. PubMed ID: 1397243
[TBL] [Abstract][Full Text] [Related]
36. Continuous infusion of mitoxantrone combined with high-dose cytarabine in refractory/relapsed acute myeloblastic leukemia and blast crisis of chronic myelogenous leukemia.
Linkesch W; Thaler J; Gattringer C; Konwalinka G
Haematol Blood Transfus; 1990; 33():330-2. PubMed ID: 2323638
[No Abstract] [Full Text] [Related]
37. [Chronic myelogenous leukemia].
Ohnishi K
Gan To Kagaku Ryoho; 2001 Sep; 28(9):1199-205. PubMed ID: 11579630
[TBL] [Abstract][Full Text] [Related]
38. Intensive remission induction therapy for chronic myeloid leukemia in blast phase with a goal of post-remission bone marrow transplant--a pilot study.
Lipton JH; Messner HA; Curtis JE; Atkins HL; Minden MD
Eur J Haematol; 1996 Jul; 57(1):42-5. PubMed ID: 8698130
[TBL] [Abstract][Full Text] [Related]
39. Complete cytogenetic and molecular remission in a case of lymphoid blast crisis in chronic myeloid leukemia with intensive chemotherapy and interferon alpha.
Fabbiano F; Santoro A; Di Trapani F; Marino MA; Pampinella M; Caronia F
Eur J Haematol; 1993 Aug; 51(2):122-3. PubMed ID: 8370420
[No Abstract] [Full Text] [Related]
40. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]